Comparative Pharmacology
Head-to-head clinical analysis: DUOPA versus LODOSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUOPA versus LODOSYN.
DUOPA vs LODOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUOPA is a combination of carbidopa and levodopa. Levodopa is a precursor of dopamine that crosses the blood-brain barrier and is converted to dopamine in the brain, replenishing depleted dopamine stores in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing the availability of levodopa for transport to the brain.
Lodosyn (carbidopa) is a peripheral decarboxylase inhibitor that inhibits the conversion of levodopa to dopamine outside the central nervous system. By blocking aromatic L-amino acid decarboxylase (AAAD) in peripheral tissues, it increases the amount of levodopa available to cross the blood-brain barrier, enhancing central dopamine levels and reducing peripheral side effects such as nausea and vomiting.
One capsule orally, once daily at bedtime. Dose strengths available: 23.75 mg/9.5 mg (carbidopa/levodopa), 36.25 mg/14.5 mg, 48.75 mg/19.5 mg, 61.25 mg/24.5 mg. Titrate based on efficacy and tolerability; maximum dose 61.25 mg/24.5 mg.
250 mg orally twice daily, in combination with levodopa/carbidopa.
None Documented
None Documented
Levodopa 1-2 h; carbidopa 1-2 h; clinical context: short t1/2 requires frequent dosing; extended-release formulation prolongs
1.5–2.5 hours in adults; prolonged in renal impairment (up to 6–8 hours).
Renal: carbidopa ~50% unchanged, levodopa minimal; fecal: ~30% of levodopa metabolites; biliary: minor
Renal: 70% unchanged; 30% as O-methylated and sulfate conjugates. Biliary/fecal: <5%.
Category C
Category C
Decarboxylase Inhibitor/Dopamine Precursor Combination
Decarboxylase Inhibitor